Exicure Inc. (NASDAQ: XCUR) received a delinquency notification from Nasdaq on May 28, 2026, for failing to file its quarterly report on time, according to a company statement.

The Listing Qualifications Department of The Nasdaq Stock Market notified Exicure that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-Q for the three months ended March 31, 2026.

The company attributed the delay to additional time required following changes in its financial reporting personnel and related filing procedures.

Exicure filed its quarterly report with the Securities and Exchange Commission on May 29, 2026, and stated it believes it has regained compliance with the Nasdaq listing rule.

The biotechnology company has undergone significant changes, having suspended its clinical and development activities and acquired a clinical-stage biotechnology company in January 2025. The acquired company develops therapeutics for hematologic diseases, with a lead program being evaluated for improving stem cell mobilization in multiple myeloma and sickle cell disease.